Head-to-head · WeighScore
PepHaūs vs Henry Meds
The verdict
PepHaūs takes it — 83/100 to 76/100.
PepHaūs grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Verified and nationwide, but priced in the upper-mid band ($152/$246).
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | PepHaūs | Henry Meds |
|---|---|---|
| WeighScore | 83/100 | 76/100 |
| Grade | B | C |
| Scorecard rank | #18 | #25 |
| Semaglutide | $152/mo | $249/mo |
| Tirzepatide | $246/mo | $349/mo |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Editorial | Editorial |
Graded #18 · B
Strengths
- LegitScript-verified, all 50 states
- Both molecules
- Transparent listed pricing
Where it loses points
- Upper-mid pricing ($152/$246)
- Injection-only
- Monitoring detail limited
Graded #25 · C
Strengths
- Simple flat-fee model
- Established brand
- Both molecules
Where it loses points
- Higher pricing than newer entrants
- Compounded only
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.